Argenx Se (ARGX) Cash & Equivalents (2015 - 2026)
Argenx Se (ARGX) posted quarterly Cash & Equivalents of $3.6 billion for Q2 2026, up 71.81% year-on-year from $2.1 billion in Q2 2025, and up 2.66% on a QoQ basis from $3.5 billion in Q4 2025.
Argenx Se (ARGX) Cash & Equivalents (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Cash & Equivalents for 12 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.
- Quarterly Cash & Equivalents rose 71.81% year-over-year to $3.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 billion (up 71.81% YoY) and the FY2025 annual result came in at $3.5 billion, up 132.73% from the prior year.
- Cash & Equivalents grew to $3.6 billion in Q2 2026 per ARGX's latest filing, from $3.5 billion in the prior quarter.
- Over the last five years, Cash & Equivalents for ARGX reached as high as $3.6 billion in Q2 2026 and fell as low as $800.7 million in Q4 2022.
- A 5-year average of $1.9 billion and a median of $1.5 billion in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents sank 40.0% — and 2023, when it surged 155.87%.
- Year by year, Cash & Equivalents stood at $800.7 million in 2022, then jumped by 155.87% to $2.0 billion in 2023, then retreated by 26.79% to $1.5 billion in 2024, then soared by 132.73% to $3.5 billion in 2025, then increased by 2.66% to $3.6 billion in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $3.6 billion, $3.5 billion, and $2.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.49 Bn |
| Jun 30, 2025 | 2.09 Bn |
| Dec 31, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Dec 31, 2023 | 2.05 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Dec 31, 2022 | 800.74 Mn |
| Jun 30, 2022 | 1.37 Bn |
| Dec 31, 2021 | 1.33 Bn |
| Jun 30, 2021 | 1.58 Bn |
| Dec 31, 2020 | 1.13 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Dec 31, 2019 | 376.98 Mn |
| Jun 30, 2019 | 190.94 Mn |
| Dec 31, 2018 | 319.81 Mn |
| Jun 30, 2018 | 203.30 Mn |
| Dec 31, 2017 | 275.46 Mn |
| Jun 30, 2017 | 109.01 Mn |
| Dec 31, 2016 | 129.74 Mn |